COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

CPTAC Researchers Produce a Highly Annotated, Publicly Accessible Database of Genes Associated with Platinum Resistance in Cancer

According to U.S. National Cancer Institute estimates, approximately 10–20% of all cancer patients will receive a platinum drug over the course of their treatment. Cisplatin, the first platinum-based anti-cancer therapy, was approved by the Food and Drug Administration (FDA) for ...

Memorandum of Understanding signed by NCI, FDA and HRSA to bring cancer diagnostic devices closer to patients, particularly members of medically underserved and geographically isolated communities

On Friday, September 17, 2021, leadership from the National Cancer Institute (NCI), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA) signed a Memorandum of Understanding (MOU) to support solutions for early cancer detection and diagnosis to improve patient ...

Machine Learning Predicts Molecular Features of Endometrial Cancer with Exceptionally High Accuracy

The CPTAC research group led by Dr. David Fenyö at NYU Langone Medical Center has demonstrated the feasibility of a machine learning image processing tool designed to assist pathologists classifying endometrial cancer. Their customized multi-resolution deep convolutional neural network (CNN) model ...

Proteogenomics Provides New Insights into Pancreatic Ductal Adenocarcinoma

Despite advances in the efficacy and specificity of cancer treatments over the last decade, pancreatic cancer remains one of the leading causes of death worldwide. The most common type of pancreatic tumor, Pancreatic Ductal Adenocarcinoma (PDAC), has distinctly poor patient outcomes due to its ...

A More Complete Molecular Picture of Lung Squamous Cell Carcinoma Comes into View

Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung ...

CPTAC Develops HER-2 Targeted Mass Spec Test (CLIA-certified)

In the era of precision medicine, human epidermal growth factor receptor 2 (HER2) is one of the important predictive and prognostic biomarkers in breast cancer. At present, conventional HER2-targeting therapies improve outcomes for patients with HER2-positive breast cancer, defined as tumors having ...

Study Finds Clues to Why Some Kidney Cancers Respond to Treatment While Others Do Not

Kidney cancer is the eighth most diagnosed cancer for both men and women in the United States, and about 76,000 new cases and nearly 14,000 deaths are expected in 2021. It is a category that includes many different kinds of cancer and is dominated by renal cell carcinoma.

AML Microenvironment Catalyzes a Step-wise Evolution to Gilteritinib Resistance

Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It is characterized by an aberrant proliferation of immature myeloblasts that infiltrate the bone marrow and impair normal hematopoiesis. AML is the most common type of acute leukemia in adults and usually worsens quickly if ...

Multiplexed Assays to Monitor Your Oncogenic Growth Signaling Network

In the age of personalized cancer therapy, genetic sequencing technologies allow clinicians to rapidly pinpoint mutations likely involved in driving patient-specific tumorigenesis and disease progression. These oncogenic mutations lead to the aberrant activation of signaling pathways involved in ...

Data Sharing Policies: From Bermuda, to Fort Lauderdale, to Amsterdam, to Sydney

Advancements in science and health care are made possible through widespread access to results from cutting-edge research, enabling scientists to use and build on this knowledge. A critically important aspect of the success of the Human Genome Project was its approach to immediately release pre- ...